The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice - PubMed (original) (raw)
The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
Theresa M Carbonaro et al. Psychopharmacology (Berl). 2015 Jan.
Abstract
Rationale: Serotonin 5-HT2A and 5-HT2C receptors are thought to be the primary pharmacological mechanisms for serotonin-mediated hallucinogenic drugs, but recently there has been interest in metabotropic glutamate (mGluR2) receptors as contributors to the mechanism of hallucinogens.
Objective: The present study assesses the role of these 5-HT and glutamate receptors as molecular targets for two tryptamine hallucinogens, N,N-dimethyltryptamine (DMT) and N,N-diisopropyltryptamine (DiPT).
Methods: Drug discrimination, head twitch, and radioligand binding assays were used. A 5-HT2AR inverse agonist (MDL100907), 5-HT2CR antagonist (SB242084), and mGluR2/3 agonist (LY379268) were tested for their ability to attenuate the discriminative stimulus effects of DMT and DiPT; an mGluR2/3 antagonist (LY341495) was tested for potentiation. MDL100907 was used to attenuate head twitches induced by DMT and DiPT. Radioligand binding studies and inosital-1-phosphate (IP-1) accumulation were performed at the 5-HT2CR for DiPT.
Results: MDL100907 fully blocked the discriminative stimulus effects of DMT, but only partially blocked DiPT. SB242084 partially attenuated the discriminative stimulus effects of DiPT, but produced minimal attenuation of DMT's effects. LY379268 produced potent, but only partial blockade of the discriminative stimulus effects of DMT. LY341495 facilitated DMT- and DiPT-like effects. Both compounds elicited head twitches (DiPT>DMT) which were blocked by MDL1000907. DiPT was a low-potency full agonist at 5-HT2CR in vitro.
Conclusions: The 5-HT2AR likely plays a major role in mediating the effects of both compounds. 5-HT2C and mGluR2 receptors likely modulate the discriminative stimulus effects of both compounds to some degree.
Figures
Fig. 1
Effects of the 5-HT2A receptor inverse agonist, MDL100907, on the discriminative stimulus effects of DMT (left panels) and DiPT (right panels). Points represent the mean and error bars represent the standard error of the mean. Top panel shows drug-appropriate responding of the test compounds. The x-axis represents dose of MDL100907. The y-axis represents percentage of drug-lever appropriate responding. Bottom panel shows rate of responding as responses per second as a function of dose. Open circles- saline control; _Open diamond_- drug control. N=7. Asterisk indicates points that are different from the drug control.
Fig. 2
Effects of the 5-HT2C receptor antagonist (SB242084) on the discriminative stimulus effects of DMT (left panels) and DiPT (right panels). Points represent the mean and error bars represent the standard error of the mean. Top panel shows drug-appropriate responding of the test compounds. The x-axis represents dose of SB242084. The y-axis represents percentage of drug-lever appropriate responding. Bottom panel shows rate of responding in responses per second (y-axis) as a function of dose. Open circles- saline control; _Open diamond_- drug control. N=7, except where shown. Asterisk indicates points that are different from the drug control.
Fig. 3
Effects of the mGlu2/3 receptor agonist (LY379268) on the discriminative stimulus effects of DMT (left panels) and DiPT (right panels). Points represent the mean and error bars represent the standard error of the mean. Top panel shows drug-appropriate responding of the test compounds in DMT/DiPT-trained rats. The x-axis represents dose of LY379268. The y-axis represents percentage of drug-lever appropriate responding. Bottom panel shows rate of responding in responses per second (y-axis) as a function of dose. Open circles- saline control; _Open diamond_- drug control. N=7, except where shown. Asterisk indicates points that are different from the drug control.
Fig. 4
Effects of the mGlu2/3 receptor antagonist (LY341495) at facilitating the effects of DMT (left panels) and DiPT (right panels). Points represent the mean and error bars represent the standard error of the mean. Top panel shows drug-appropriate responding of the test compounds in DMT/DiPT-trained rats. The x-axis represents dose of DMT/DiPT. The y-axis represents percentage of drug-lever appropriate responding. Bottom panel shows rate of responding in responses per second (y-axis) as a function of dose. _Open triangles_- Dose-effect curve of DMT and DiPT; _Closed triangles_- 0.5 mg/kg of LY341495; Closed circles- 2.5 mg/kg LY341495. Open circles- saline control; _Open diamond_- drug control; open squares- LY341495 alone. N=7, except where shown. Asterisk indicates points that are different from the saline control.
Fig. 5
Effects of the 5-HT2A receptor inverse agonist, MDL100907 on head twitches induced by hallucinogens in C57Bl/6 mice. The x-axis represents vehicle controls or dose of DOI, DMT, or DiPT alone in combination with MDL100907. The y-axis represents mean head twitches in a 10-minute period. Error bars show the standard error of the mean. MDL indicates MDL100907. Sal indicates saline control. # indicates points different from hallucinogen alone (light gray bars); Asterisk indicates points different from the saline controls (Sal).
Similar articles
- Discriminative stimulus effects of N,N-diisopropyltryptamine.
Carbonaro TM, Forster MJ, Gatch MB. Carbonaro TM, et al. Psychopharmacology (Berl). 2013 Mar;226(2):241-6. doi: 10.1007/s00213-012-2891-x. Epub 2012 Oct 16. Psychopharmacology (Berl). 2013. PMID: 23070023 Free PMC article. - Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Smith RL, et al. Pharmacol Biochem Behav. 1998 Nov;61(3):323-30. doi: 10.1016/s0091-3057(98)00110-5. Pharmacol Biochem Behav. 1998. PMID: 9768567 - Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Fantegrossi WE, et al. Pharmacol Biochem Behav. 2006 Jan;83(1):122-9. doi: 10.1016/j.pbb.2005.12.015. Epub 2006 Feb 3. Pharmacol Biochem Behav. 2006. PMID: 16460788 - The hallucinogenic world of tryptamines: an updated review.
Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M. Araújo AM, et al. Arch Toxicol. 2015 Aug;89(8):1151-73. doi: 10.1007/s00204-015-1513-x. Epub 2015 Apr 16. Arch Toxicol. 2015. PMID: 25877327 Review. - Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R, Kumar Bora P, Saikia J, Konwar P, Sarkar A, Kemprai P, Proteem Saikia S, Haldar S, Slater A, Banik D. Barman R, et al. Phytochemistry. 2024 Feb;218:113928. doi: 10.1016/j.phytochem.2023.113928. Epub 2023 Nov 29. Phytochemistry. 2024. PMID: 38035973 Review.
Cited by
- CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.
Gobbi G. Gobbi G. J Psychiatry Neurosci. 2024 Sep 19;49(5):E301-E318. doi: 10.1503/jpn.240037. Print 2024 Sep-Oct. J Psychiatry Neurosci. 2024. PMID: 39299781 Free PMC article. Review. - Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.
Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, Islam MN, Holy M, Niello M, Pubill D, Camarasa J, Escubedo E, Sitte HH, López-Arnau R. Puigseslloses P, et al. Mol Psychiatry. 2024 Aug;29(8):2346-2358. doi: 10.1038/s41380-024-02506-8. Epub 2024 Mar 14. Mol Psychiatry. 2024. PMID: 38486047 Free PMC article. - Discovery and In Vitro Characterization of SPL028: Deuterated N,_N_-Dimethyltryptamine.
Layzell M, Rands P, Good M, Joel Z, Cousins R, Benway T, James E, Routledge C. Layzell M, et al. ACS Med Chem Lett. 2023 Aug 31;14(9):1216-1223. doi: 10.1021/acsmedchemlett.3c00143. eCollection 2023 Sep 14. ACS Med Chem Lett. 2023. PMID: 37736183 Free PMC article. - The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. Mastinu A, et al. Int J Mol Sci. 2023 Jan 10;24(2):1329. doi: 10.3390/ijms24021329. Int J Mol Sci. 2023. PMID: 36674849 Free PMC article. Review. - Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
Rossi GN, Guerra LTL, Baker GB, Dursun SM, Saiz JCB, Hallak JEC, Dos Santos RG. Rossi GN, et al. Biomolecules. 2022 Nov 2;12(11):1618. doi: 10.3390/biom12111618. Biomolecules. 2022. PMID: 36358968 Free PMC article. Review.
References
- Appel JB, West WB, Rolandi WG, Alici T, Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacology Biochemistry and Behavior. 1999;64:353–358. - PubMed
- Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther. 1999;291:161–70. - PubMed
- Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M. Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology. 2012;62:2184–91. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources